@dansfera: That green light investors saw for LibroVant after an FDA adcom waiver? It was a massive trap. The actual outcome was a Complete Response Letter because of tricky pharmacokinetic issues, forcing a study redo before eventual approval months later. This is the reality check every stock trader needs about regulatory filings. Don't celebrate until the ink is dry! \#FDA \#InvestingTips \#StockMarket \#Biotech \#PharmaNews

dansfera

Open In TikTok:

Region: US

Friday 09 January 2026 20:01:30 GMT